Royalty Pharma PLC (RPRX) Social Stream
ROYALTY PHARMA PLC (RPRX) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering RPRX.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-10 | 8 | $56.001 | $46 | $51.714 | $38.33 | 34.92% |
| 2022-02-02 | 7 | $56 | $46 | $51.714 | $38.33 | 34.92% |
| 2022-03-08 | 7 | $56 | $46 | $51.142 | $38.33 | 33.43% |
| 2022-04-06 | 7 | $56 | $48 | $51.428 | $38.33 | 34.17% |
| 2022-05-06 | 7 | $56 | $48 | $51.428 | $38.33 | 34.17% |
| 2022-06-09 | 9 | $56 | $48 | $52.111 | $38.33 | 35.95% |
| 2022-06-14 | 10 | $56 | $47 | $51.6 | $38.33 | 34.62% |
| 2022-08-03 | 10 | $57 | $47 | $52.3 | $38.33 | 36.45% |
| 2022-10-12 | 10 | $57 | $47 | $52.6 | $38.33 | 37.23% |
| 2022-10-27 | 10 | $57 | $47 | $52.8 | $38.33 | 37.75% |
| 2022-11-28 | 9 | $57 | $47 | $53.111 | $38.33 | 38.56% |
| 2022-12-06 | 9 | $57 | $47 | $52.777 | $38.33 | 37.69% |
| 2023-01-10 | 9 | $57 | $47 | $52.333 | $38.33 | 36.53% |
The Trend in the Analyst Price Target
RPRX's average price target has moved up $0.03 over the prior 160 days.
Over the past 50 weeks, RPRX's average upside potential has been 26.25%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-04-14 | 7 | 56 | 48 | 51.428 | 44.10 | 16.62% |
| 2022-05-06 | 8 | 56 | 48 | 51.428 | 39.72 | 29.48% |
| 2022-08-05 | 10 | 57 | 47 | 52.600 | 42.45 | 23.91% |
| 2022-08-10 | 10 | 57 | 47 | 52.600 | 43.92 | 19.76% |
| 2022-10-18 | 10 | 57 | 47 | 52.800 | 42.02 | 25.65% |
RPRX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.17 | 7 | 2 | 0 | 0 | 0 | 9 |
The Trend in the Broker Recommendations
RPRX's average broker recommendation rating worsened by 0.02 over the prior 122 days.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- ROYALTY PHARMA PLC's variance in analysts' estimates is lower than -105.91% of all US stocks.
- ROYALTY PHARMA PLC's number of analysts covering the stock is higher than 303% of stocks in the large market cap category.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, ROYALTY PHARMA PLC's upside potential (average analyst target price relative to current price) is greater than 309.28% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, ROYALTY PHARMA PLC's average analyst price target is higher than 919.17% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ROYALTY PHARMA PLC are CVAC, MRVI, and ABCL.
View All Top Stocks by Price Target
Make investment decisions regarding RPRX using the data that counts. Try POWR Ratings for free.